The Role of P16, P53, KI-67 and PD-L1 Immunostaining in Primary Vaginal Cancer.
anti-VEGF-therapy
immunotherapy
vaginal cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Feb 2023
07 Feb 2023
Historique:
received:
10
12
2022
revised:
02
02
2023
accepted:
04
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
To analyze clinical, pathological and immunohistochemical correlates of survival in vaginal cancer patients. Retrospective analysis of primary vaginal cancer patients, treated at the Department of Gynecology and Gynecological Oncology of the University Hospital Bonn between 2007 and 2021. The study cohort comprised 22 patients. The median age was 63 years (range: 32-87 years). Squamous cell histology was present in 20 patients. Five-year OS in Stage I, II, III and IV was 100%, 56.25%, 0% and 41.67%, respectively ( P16 expression, absence of lymph- or hemangiosis, nodal negative disease and an age below 64 years show improved survival rates in PVC. Tumoral PD-L1 expression as well as PD-L1 expression on immune cells is frequent in PVC, without impacting survival. Within our study cohort, long-term survivors with recurrent PVC are treated with anti-VEGF and immunotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
To analyze clinical, pathological and immunohistochemical correlates of survival in vaginal cancer patients.
METHODS
METHODS
Retrospective analysis of primary vaginal cancer patients, treated at the Department of Gynecology and Gynecological Oncology of the University Hospital Bonn between 2007 and 2021.
RESULTS
RESULTS
The study cohort comprised 22 patients. The median age was 63 years (range: 32-87 years). Squamous cell histology was present in 20 patients. Five-year OS in Stage I, II, III and IV was 100%, 56.25%, 0% and 41.67%, respectively (
CONCLUSION
CONCLUSIONS
P16 expression, absence of lymph- or hemangiosis, nodal negative disease and an age below 64 years show improved survival rates in PVC. Tumoral PD-L1 expression as well as PD-L1 expression on immune cells is frequent in PVC, without impacting survival. Within our study cohort, long-term survivors with recurrent PVC are treated with anti-VEGF and immunotherapy.
Identifiants
pubmed: 36831389
pii: cancers15041046
doi: 10.3390/cancers15041046
pmc: PMC9954710
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Gynecol Cancer. 2022 Mar;32(3):344-351
pubmed: 35256422
Int J Gynecol Cancer. 2011 Jul;21(5):923-9
pubmed: 21666483
Gynecol Oncol. 2020 Nov;159(2):456-463
pubmed: 32972784
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
N Engl J Med. 2021 Nov 11;385(20):1856-1867
pubmed: 34534429
Obstet Gynecol. 2009 Apr;113(4):917-924
pubmed: 19305339
Gynecol Oncol. 2020 May;157(2):423-428
pubmed: 32139148
Mol Med Rep. 2017 Mar;15(3):1063-1070
pubmed: 28075442
Int J Gynecol Pathol. 2019 Nov;38(6):588-596
pubmed: 31593028
Sci Rep. 2019 Sep 16;9(1):13404
pubmed: 31527697
J Clin Oncol. 2019 Nov 1;37(31):2825-2834
pubmed: 31487218
Pathologe. 2021 Feb;42(1):116-124
pubmed: 33346872
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:14-21
pubmed: 30306589
Int J Gynecol Pathol. 2011 Sep;30(5):497-504
pubmed: 21804386
Semin Diagn Pathol. 2015 Sep;32(5):409-18
pubmed: 25862555
Gynecol Oncol. 2007 May;105(2):470-4
pubmed: 17292459
Gynecol Oncol. 2022 Aug;166(2):211-218
pubmed: 35361487
Acta Obstet Gynecol Scand. 2021 Dec;100(12):2144-2156
pubmed: 34546565
Oncol Res Treat. 2017;40(11):697-701
pubmed: 29065399
Lancet. 2017 Oct 7;390(10103):1654-1663
pubmed: 28756902
Pathology. 2021 Feb;53(2):141-156
pubmed: 33388161
Ann Oncol. 2021 May;32(5):661-672
pubmed: 33736924
Front Oncol. 2019 Oct 15;9:1067
pubmed: 31681600
Clin Cancer Res. 2015 Dec 15;21(24):5480-7
pubmed: 26672085
Arch Gynecol Obstet. 2009 Jul;280(1):25-32
pubmed: 19043726
Front Immunol. 2021 Jul 23;12:686879
pubmed: 34367146
Mod Pathol. 2020 Aug;33(8):1595-1605
pubmed: 32203095
Br J Cancer. 2014 Mar 18;110(6):1561-70
pubmed: 24525695
Cancer Gene Ther. 2015 Sep;22(9):454-62
pubmed: 26337747
Sci Rep. 2021 Feb 11;11(1):3667
pubmed: 33574401
N Engl J Med. 1971 Apr 15;284(15):878-81
pubmed: 5549830
N Engl J Med. 2022 Feb 10;386(6):544-555
pubmed: 35139273
J Clin Oncol. 2019 Jun 10;37(17):1470-1478
pubmed: 30943124
Int J Mol Sci. 2022 Feb 05;23(3):
pubmed: 35163748
Gynecol Oncol. 2012 Apr;125(1):194-9
pubmed: 22226684
Gynecol Oncol. 2003 Sep;90(3):547-51
pubmed: 13678722
Semin Diagn Pathol. 2021 Jan;38(1):50-61
pubmed: 33032902
Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1060-1078
pubmed: 31680701
Front Immunol. 2020 Dec 17;11:596825
pubmed: 33424844
Sci Transl Med. 2016 Apr 13;8(334):334ra52
pubmed: 27075626
Histopathology. 2010 Dec;57(6):907-16
pubmed: 21166704
Gynecol Oncol. 2013 May;129(2):406-11
pubmed: 23402906